Catalent Announces Leadership Changes in Biologics BizBy
Catalent Pharma Solutions has made leadership changes within its biologics business. The changes follows its $950-million acquisition in 2017 of Cook Pharmica, a Bloomington, Indiana contract development and manufacturing organization of biologic drug substances and parenteral drug products, and with it the addition of an 875,000 square-foot facility in Bloomington to provide biologics development, analytical services, and drug-substance and drug-product manufacturing.
Tedd Green, former President of Cook Pharmica, will become Senior Vice President of Catalent Biologics and will have responsibility for the entire biologics business. He will continue to report to Barry Littlejohns, President, Catalent Biologics and Specialty Drug Delivery, and will also act as a member of Catalent’s executive leadership team. Green will be based at the Bloomington facility.
Mike Riley will become Vice President and General Manager of Drug Substance and Bioanalytical Services for Catalent Biologics. He will lead the company’s biologics manufacturing business, including its mammalian cell-line engineering and biomanufacturing capabilities, and its bioanalytical capabilities based at several sites across Catalent’s global network.
Cory Lewis will take on the new role of Vice President and General Manager of the Catalent Biologics Drug Product business, with a focus on growing the Catalent Biologics drug-product offerings both in the US and in Europe.
In a further move, Ryan Hawkins has been appointed as General Manager of the Bloomington site, having been helpful through his contributions and leadership over the last 10 years.
With the acquisition of Cook Pharmica, Catalent advanced its position in integrated biologics development, clinical- and commercial-scale manufacturing, and finished-product supply. The addition of the facilities brought expertise in liquid and lyophilized sterile formulation and fill-finish across vials, prefilled syringes, auto-injectors, cartridges, and safety devices, and 2,500 liter biomanufacturing capacity to augment Catalent’s existing biologics infrastructure.
Source: Catalent Pharma Solutions